Travere Therapeutics spent the first half of 2026 converting a single approved medicine into a broader commercial and pipeline story. A rare-disease drugmaker built around FILSPARI, its treatment for two serious kidney conditions, Travere reached full approval in a new indication, posted its first quarter of non-GAAP profitability, and struck a licensing deal for an early-stage candidate.
Travere ranks among the largest disclosed equity positions in Armistice Capital’s most recent
